News

As part of the development, Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have signed an agreement to

Novartis and GSK have agreed to provide £2.8m ($3.6m) for the Africa Genomic Research Approach for Diversity and Optimizing Therapeutics (GRADIENT) project (Project Africa GRADIENT), over the next

The companies will leverage Cure Genetics’ VELP platform to develop the vectors. Under the partnership, Boehringer’s experience in disease biology and gene therapy development will be combined with

Etana now has the right to sell BYVASDA in the country and in return, Innovent Biologics will receive milestones for the development and commercialisation along with double-digit royalties

The viral vector manufacturing arm of Novasep offers contract manufacturing services for vaccines and therapies to biotechnology and biopharma companies. Established over 20 years ago, the business has

The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. Earlier, the Data and

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced,

The financing will support the full Phase 3 development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. The drug, a cholesteryl ester transfer protein (CETP) inhibitor,

The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. ALCL is a rare form of non-Hodgkin lymphoma